New COVID Treatments Approved

The TGA has approved two oral anti-viral COVID treatments for use in Australia.
Molnupiravir and Paxlovid have been found to be effective in treating people with mild to moderate COVID-19 who have a high risk of progressing to severe disease, reducing admissions to hospital and ICU and potential death.
The Government has secured 800,000 courses of these treatments in total, with the first deliveries of both medicines anticipated over the coming weeks.
As with all COVID-19 treatments, both of these medications have been rigorously assessed by the TGA for safety, quality and effectiveness before being provisionally registered for use in Australia.
Menu